Xtandi 40 MG capsule 120S
Ended Awarded
- Contract number
- SPE2DB25FYQ15
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,934
Award facts
- Contract value 100% obligated
- $12,934.05 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $12,934.05 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on September 16, 2025, with an ultimate completion date of September 17, 2025, carries no set-aside designation. The award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.99 billion blanket agreement through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting Department of Defense healthcare facilities worldwide.
Xtandi, an oncology treatment medication, represents one of many specialized pharmaceutical products DMS Pharmaceutical Group supplies to federal military health systems through its established DLA relationship. The company's core business involves distributing branded and generic prescription drugs, biologics, and medical consumables directly to military healthcare facilities across the nation. As a consistent federal contractor without set-aside restrictions, DMS Pharmaceutical Group leverages its woman-owned small business status to compete effectively in federal procurement markets, maintaining a robust portfolio of pharmaceutical deliveries that spans contraceptive devices, oncology treatments, vaccines, and various specialty medications essential to Department of Defense operations.
Quick answers
Who was awarded contract SPE2DB25FYQ15?
SPE2DB25FYQ15 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 16, 2025.
How much is contract SPE2DB25FYQ15 worth?
The government has obligated $12,934 on SPE2DB25FYQ15.
Is contract SPE2DB25FYQ15 an order under another contract?
Yes. SPE2DB25FYQ15 is a delivery order under SPE2DB22D9316, an indefinite delivery contract.
Was contract SPE2DB25FYQ15 competed?
The extent of competition for SPE2DB25FYQ15 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award